Adhera Therap 
Welcome,         Profile    Billing    Logout  
 2 Products   30 Diseases   2 Products   1 Trial   53 News 
  • ||||||||||  tolimidone (MTX228) / Bukwang Pharma, Biodexa Pharma
    Trial primary completion date:  An Adaptive Design Study of MTX228 (clinicaltrials.gov) -  Nov 6, 2024   
    P2,  N=24, Not yet recruiting, 
    Trial primary completion date: Oct 2024 --> Oct 2026
  • ||||||||||  tolimidone (MTX228) / Bukwang Pharma, Biodexa Pharma
    New P2 trial:  An Adaptive Design Study of MTX228 (clinicaltrials.gov) -  Jun 25, 2024   
    P2,  N=24, Not yet recruiting, 
  • ||||||||||  tolimidone (MLR-1023) / Melior, Bukwang Pharma, Adhera Therap
    Preclinical, Journal:  MLR-1023 Treatment in Mice and Humans Induces a Thermogenic Program, and Menthol Potentiates the Effect. (Pubmed Central) -  Nov 29, 2021   
    P2a
    The TRPM8 agonist, menthol, potentiated the effect of MLR-1023 on the upregulation of genes for energy expenditure and insulin sensitivity in human adipocytes, and reduced fasting blood glucose in mice. The amplification of the thermogenic program by MLR-1023 and menthol in the absence of adrenergic activation will likely be well-tolerated, and bears investigation in a clinical trial.
  • ||||||||||  mesocarb (MLR-1019) / Melior
    Journal:  Norbornene-Functionalized Plant Oils for Biobased Thermoset Films and Binders of Silicon-Graphite Composite Electrodes. (Pubmed Central) -  Dec 1, 2020   
    Cell performance investigation showed that the silicone/MCMB composite electrode bearing the NBD-cross-linked NB-functionalized plant oil binder exhibited a higher C-rate and cycle-life performance than that using a conventional poly(vinylidene fluoride) (PVDF) binder. Finally, the electrode based on the bioderived binder exhibited a high specific charge capacity of 620 mA h g at 0.5 C.
  • ||||||||||  mesocarb (MLR-1019) / Melior
    Journal:  Solid-electrolyte interphase nucleation and growth on carbonaceous negative electrodes for Li-ion batteries visualized with in situ atomic force microscopy. (Pubmed Central) -  May 24, 2020   
    Using this approach, we observed SEI nucleation and growth on highly oriented pyrolytic graphite (HOPG), MesoCarbon MicroBeads (MCMB) graphite, and non-graphitizable amorphous carbon (hard carbon)...The comparative observations revealed that the electrode potentials for SEI formation differ depending on the nature of the electrode material, whereas the adhesion of SEI to the electrode surface clearly correlates with the surface roughness of the electrode. Finally, the same approach applied to a positive LiNiMnCoO electrode did not reveal any signature of cathodic SEI thus demonstrating fundamental differences in the stabilization mechanisms of the negative and positive electrodes in Li-ion batteries.
  • ||||||||||  MLR-1023 / Melior, Bukwang Pharma, bafetinib (INNO-406) / CytRx
    Journal:  Quercetin as a Lyn kinase inhibitor inhibits IgE-mediated allergic conjunctivitis. (Pubmed Central) -  Feb 14, 2020   
    This study illustrated the use of quercetin for the treatment of allergic conjunctivitis, which might act through its ability to inhibit Lyn/PLCγ/IP3R-Ca, Lyn/ERK1/2, and Lyn/NF-κB signaling. The inhibition of Lyn likely represents a major mechanism by which quercetin dampens the inflammatory response in AC disease models.
  • ||||||||||  tolimidone (MTX228) / Bukwang Pharma, Biodexa Pharma
    Enrollment closed:  An Add-on Study of MLR-1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy (clinicaltrials.gov) -  Jan 9, 2019   
    P2,  N=400, Active, not recruiting, 
    The inhibition of Lyn likely represents a major mechanism by which quercetin dampens the inflammatory response in AC disease models. Recruiting --> Active, not recruiting
  • ||||||||||  tolimidone (MTX228) / Bukwang Pharma, Biodexa Pharma
    Trial completion:  Adult Subjects With Uncontrolled Type 2 Diabetes (clinicaltrials.gov) -  Sep 26, 2016   
    P2a,  N=149, Completed, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Completed
  • ||||||||||  tolimidone (MTX228) / Bukwang Pharma, Biodexa Pharma
    Enrollment closed, Enrollment change, Trial primary completion date:  Adult Subjects With Uncontrolled Type 2 Diabetes (clinicaltrials.gov) -  Dec 29, 2015   
    P2a,  N=149, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=115 --> 149 | Trial primary completion date: Jul 2015 --> Jan 2016
  • ||||||||||  tolimidone (MTX228) / Bukwang Pharma, Biodexa Pharma
    New P2a trial:  Adult Subjects With Uncontrolled Type 2 Diabetes (clinicaltrials.gov) -  Dec 17, 2014   
    P2a,  N=120, Recruiting,